Innoviva Share Holder Equity 2012-2025 | INVA
Innoviva share holder equity from 2012 to 2025. Share holder equity can be defined as the sum of preferred and common equity items
|
Innoviva Annual Share Holder Equity (Millions of US $) |
|
|---|---|
| 2024 | $691 |
| 2023 | $675 |
| 2022 | $566 |
| 2021 | $526 |
| 2020 | $608 |
| 2019 | $342 |
| 2018 | $159 |
| 2017 | $-243 |
| 2016 | $-353 |
| 2015 | $-343 |
| 2014 | $-223 |
| 2013 | $299 |
| 2012 | $155 |
| 2011 | $-87 |
|
Innoviva Quarterly Share Holder Equity (Millions of US $) |
|
|---|---|
| 2025-09-30 | $1,010 |
| 2025-06-30 | $715 |
| 2025-03-31 | $647 |
| 2024-12-31 | $691 |
| 2024-09-30 | $669 |
| 2024-06-30 | $666 |
| 2024-03-31 | $704 |
| 2023-12-31 | $675 |
| 2023-09-30 | $627 |
| 2023-06-30 | $555 |
| 2023-03-31 | $561 |
| 2022-12-31 | $566 |
| 2022-09-30 | $641 |
| 2022-06-30 | $565 |
| 2022-03-31 | $552 |
| 2021-12-31 | $526 |
| 2021-09-30 | $492 |
| 2021-06-30 | $394 |
| 2021-03-31 | $697 |
| 2020-12-31 | $608 |
| 2020-09-30 | $535 |
| 2020-06-30 | $493 |
| 2020-03-31 | $406 |
| 2019-12-31 | $342 |
| 2019-09-30 | $284 |
| 2019-06-30 | $247 |
| 2019-03-31 | $200 |
| 2018-12-31 | $159 |
| 2018-09-30 | $-108 |
| 2018-06-30 | $-155 |
| 2018-03-31 | $-213 |
| 2017-12-31 | $-243 |
| 2017-09-30 | $-223 |
| 2017-06-30 | $-297 |
| 2017-03-31 | $-334 |
| 2016-12-31 | $-353 |
| 2016-09-30 | $-368 |
| 2016-06-30 | $-363 |
| 2016-03-31 | $-362 |
| 2015-12-31 | $-343 |
| 2015-09-30 | $-323 |
| 2015-06-30 | $-294 |
| 2015-03-31 | $-260 |
| 2014-12-31 | $-223 |
| 2014-09-30 | $-193 |
| 2014-06-30 | $-188 |
| 2014-03-31 | $263 |
| 2013-12-31 | $299 |
| 2013-09-30 | $330 |
| 2013-06-30 | $86 |
| 2013-03-31 | $92 |
| 2012-12-31 | $155 |
| 2012-09-30 | $173 |
| 2012-06-30 | $189 |
| 2012-03-31 | $6 |
| 2011-12-31 | $-87 |
| 2011-09-30 | $-59 |
| 2011-06-30 | $-37 |
| 2011-03-31 | $-28 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.477B | $0.359B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $976.553B | 46.97 |
| Johnson & Johnson (JNJ) | United States | $529.009B | 21.15 |
| AbbVie (ABBV) | United States | $383.081B | 22.94 |
| Roche Holding AG (RHHBY) | Switzerland | $344.774B | 0.00 |
| Novartis AG (NVS) | Switzerland | $302.393B | 16.03 |
| Merck (MRK) | United States | $275.430B | 12.83 |
| Novo Nordisk (NVO) | Denmark | $255.041B | 14.95 |
| Pfizer (PFE) | United States | $147.203B | 8.09 |
| Sanofi (SNY) | France | $115.780B | 11.20 |
| Bayer (BAYRY) | Germany | $47.824B | 8.39 |